Talking Cancer: Conversations with Trailblazers, Advocates, Patients, and Medical Ambassadors
Interview with Patient Advocate Marcia Horn, CEO, ICAN Network
Precision medicine reduces unnecessary risks to patients including hazardous side effects as well as ineffective treatments (“trial and error” medicine).
Genomics in Precision Medicine
We often hear “Don’t take anything personally”. However, that is not the case in terms of precision medicine. In 2015, the U.S. government launched the "Precision Medicine Initiative".
Talking Cancer: Conversations with Trailblazers, Advocates, Patients and Medical Ambassadors
As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.
Trends – Epigenetic Biomarkers
In the oncology biomarker field, there are obvious trends in technology and markers as well as testing strategies.
Jemperli blog post - please share your thoughts!
We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.
Biomarker Types and CDx Biomarkers
The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.
Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.